Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The pooled prevalence of chronic painful neuropathy is 41.22% among individuals with chemotherapy-induced peripheral neuropathy (CIPN).

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Understanding the prevalence and predictors of chronic painful chemotherapy-induced peripheral neuropathy is critical for promoting early diagnosis and developing personalized treatment strategies.

Patients treated with platinum-based agents and taxanes had the highest prevalence of chronic painful CIPN (40.44% and 38.35%, respectively). HealthDay News — The pooled prevalence of chronic ...

Among patients with chemotherapy-induced peripheral neuropathy, those treated with platinum-based agents, taxanes had highest prevalence. (HealthDay News) — The pooled prevalence of chronic ...

“Our findings emphasize that chronic painful chemotherapy-induced peripheral neuropathy represents a substantial global health challenge, affecting more than 40% of those diagnosed,” concluded ...